STERIS plc filings document material events for an Ireland-incorporated operating company with ordinary shares traded as STE on the New York Stock Exchange. Recent Form 8-K reports cover results of operations and financial condition, attached earnings releases, director appointments and retirements, officer transition arrangements, and compensation-related amendments.
The filing record also identifies STERIS securities registered under Section 12(b), including ordinary shares and NYSE-listed senior notes due 2031 and 2051. These disclosures frame the company’s capital structure, governance actions, executive-compensation matters, and periodic operating-result announcements for its infection-prevention and life sciences business.
STERIS plc director Cynthia L. Feldmann received equity awards on 2026-08-10. She was granted 1,506 nonqualified stock options to buy ordinary shares at an exercise price of $238.91 per share, fully vested and exercisable immediately, expiring on 2036-08-10. She also received 512 fully vested Career Restricted Stock Units, each representing one ordinary share to be settled six months after her Board service ends, bringing her directly held Career RSUs to 8,640 units.
Boulud Pierre reported acquisition or exercise transactions in this Form 4 filing.
STERIS plc reported that director Pierre Boulud received a grant of 1,025 Career Restricted Stock Units, each representing the right to receive one STERIS ordinary share. The units are fully vested immediately and will be settled in ordinary shares six months after the cessation of the Director's Board service, bringing his reported direct holdings in these units to 1,392.
STERIS plc director Esther M. Alegria received new equity-based compensation. On 2026-08-10 she was granted 1,506 nonqualified stock options with an exercise price of $238.91 per share, expiring on 2036-08-10; these options are fully vested and exercisable immediately. She was also granted 512 Career Restricted Stock Units, each representing one ordinary share, which are fully vested and will be settled in shares six months after her Board service ends. Following these awards, her directly held derivative interests reported in this filing total 3,408 Career RSUs and 1,506 stock options.
STERIS plc director Sohi Mohsen submitted notice of a proposed sale of 4,058 ordinary shares, with an aggregate market value of $956,779 and an approximate sale date of August 12, 2026. The shares are listed as acquired from STERIS plc on August 12, 2026, through an employee stock option exercise, with payment by broker cashless exercise. Charles Schwab & Co., Inc. is named as the broker.
STERIS plc reported stronger fiscal 2027 first‑quarter results, with revenue up 7.3% to $1,492.7 million, driven by higher volume in Healthcare and Life Sciences and pricing across all segments. Product revenue was $737.2 million and service revenue $755.5 million.
Gross margin improved to 45.8% from 45.1% as pricing, productivity and mix more than offset inflation. Income from operations rose to $285.8 million from $246.0 million, while net income attributable to shareholders increased to $200.1 million, or $2.04 diluted EPS, from $177.4 million, or $1.79.
Operating cash flow was $367.1 million and free cash flow $279.6 million after $87.5 million of capital spending. Total debt was $1,893.7 million, giving a debt‑to‑total capital ratio of 20.9%. The company repurchased 0.5 million shares for $100.0 million and began a new $1,000.0 million buyback program with $900.0 million remaining.
Remaining performance obligations were $1,541.4 million, with most expected to convert to revenue within a year. After largely completing a prior European restructuring, STERIS announced a new North Carolina chemistries consolidation, expecting $55–$70 million of pre‑tax restructuring charges through fiscal 2030.
STERIS plc held its 2026 Annual General Meeting of Shareholders on July 31, 2026. There were 97,457,680 ordinary shares outstanding and entitled to vote, and holders of 89,909,204 shares, or 92.25%, were present in person or by proxy, constituting a quorum. Effective upon completion of the meeting, the size of the Board of Directors was set at nine members.
Shareholders cast votes for nine director nominees, including Dr. Esther M. Alegria, Pierre Boulud, Daniel A. Carestio, Cynthia L. Feldmann, Christopher S. Holland, Paul E. Martin, Dr. Nirav R. Shah, Louis A. Shapiro and Dr. Mohsen M. Sohi, with each nominee receiving tens of millions of votes in favor. The results also detail votes for and against several additional management proposals, with broker non-votes where applicable.
STERIS plc reports that Director Pierre Boulud, whose election and the expansion of the Board from nine to ten members were previously disclosed, has received his initial committee assignments. Effective July 31, 2026, he was appointed to the Board’s Audit Committee and its Compliance and Technology Committee.
The company notes that no other changes were made to the matters previously reported regarding the Board’s composition or Mr. Boulud’s role.
STERIS plc reported fiscal 2027 first-quarter results and outlined a new chemistries consolidation plan. Revenue rose 7% to $1.5 billion, with constant currency organic growth of 6%. Net income attributable to shareholders was $200.1 million and diluted EPS was $2.04, up from $1.79. Adjusted EPS increased to $2.59 from $2.34.
Healthcare revenue grew 8% to $1.05 billion, Applied Sterilization Technologies 6% to $297.6 million, and Life Sciences 9% to $146.7 million, with operating income higher in all three segments. Operating cash flow was $367.1 million and free cash flow $279.6 million, lower than the prior year mainly because working capital contributed less, partly offset by higher net income.
The company announced a targeted restructuring linked to a new formulated chemistries Center of Excellence in North Carolina. STERIS expects total pre-tax restructuring charges of $55–$70 million, including $40–$50 million of cash costs and $15–$20 million of non-cash charges, with completion anticipated during fiscal 2030; these will be excluded from adjusted earnings. The company reaffirmed its fiscal 2027 outlook for 7–8% reported revenue growth and adjusted EPS of $11.10–$11.30, while increasing planned capital expenditures to about $450 million and lowering expected free cash flow to approximately $800 million.
STERIS plc director Mohsen Sohi exercised a fully vested option to purchase 3,781 ordinary shares at $71.40 per share, an award originally received in connection with the company’s 2019 redomiciliation. In a net cashless exercise, options relating to 1,837 shares were surrendered to pay the option price. After these transactions, he directly owned 24,305 ordinary shares. The filing indicates the transactions were not made under a Rule 10b5-1 trading plan.
STERIS plc senior vice president, general counsel and secretary John Adam Zangerle reported an open-market sale of 1,419 Ordinary Shares at $209.28 per share. After this transaction, he directly holds 35,259 Ordinary Shares.
As of June 15, 2026, 8,239 of these Ordinary Shares are restricted, with restrictions scheduled to lapse in stages between June 2, 2027 and June 4, 2029.